According to our new market research study on “Middle East & Africa RNAi Therapeutics Market to 2027 – Regional Analysis and Forecast – by Molecule Type, Route of Administration, Application, and End User,” the Middle East & Africa RNAi therapeutics market is expected to reach US$ 29.02 million by 2027 from US$ 16.76 million in 2019, it is estimated to grow at a CAGR of 7.2% from 2020 to 2027. The report provides trends prevailing in the Middle East & Africa RNAi therapeutics market and the factors driving the market growth along with those hindering it.

In 2019, the small interfering RNAs (siRNA) segment accounted for higher share of the market. Growth of this segment is attributed to increasing preference for small interfering RNAs for drug development and growing number of research partnerships. The microRNA (miRNA) segment is expected to register higher CAGR in the RNAi therapeutics market during the forecast period.

The growth of the Middle East & Africa RNAi therapeutics market is mainly attributed to growing prevalence of chronic conditions and rising investments for development of RNAi therapeutics. Additionally, increasing awareness about RNAi therapies and their benefits are anticipated to boost the research and innovations of RNAi therapeutics in the region, which would eventually drive the market growth. However, the high cost of RNAi therapy development is the major factor hindering the market growth in Middle East & Africa.

Benitec Biopharma; Olix Pharmaceuticals, Inc; GlaxoSmithKline plc; Alnylam Pharmaceuticals, Inc; and Arrowhead Pharmaceuticals, Inc are among the leading companies operating in the Middle East & Africa RNAi therapeutics market.

The report segments the Middle East & Africa RNAi therapeutics market as follows:

Middle East & Africa RNAi Therapeutics Market – by Molecule Type

• Small Interfering RNAs (siRNA)
• MicroRNA (miRNA)

Middle East & Africa RNAi Therapeutics Market – by Route of Administration

• Pulmonary Delivery
• Intravenous Injections
• Intradermal Injections
• Intraperitoneal Injections
• Others

Middle East & Africa RNAi Therapeutics Market – by Application

• Oncology
• Cardiovascular
• Respiratory Disorders
• Renal Diseases
• Genetic Disorders
• Neurodegenerative Disorders
• Infectious Diseases
• Others

Middle East & Africa RNAi Therapeutics Market – by End User

• Research and Academic Laboratories
• Hospitals
• Diagnostic Laboratories

Middle East & Africa RNAi Therapeutics Market – by Country

• Middle East & Africa
• UAE
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa